Bringing the Oncology Community Together

Dr. Landgren on Combinations in Newly Diagnosed Myeloma

C. Ola Landgren, MD, PhD
Published Online: Monday, December 16, 2013
C. Ola Landgren, MD, PhD, a senior investigator in the Multiple Myeloma Section of the National Cancer Institute, discusses a phase II trial that explored the combination of carfilzomib, lenalidomide, and dexamethasone followed by maintenance lenalidomide in patients with newly diagnosed multiple myeloma.

In the study, patients received 8 cycles of the combination therapy followed by 24 cycles of monthly lenalidomide. Carfilzomib was initially administered at 20 mg/m2 but was later switched to 36 mg/m2 on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. Lenalidomide was administered at 25 mg days 1-21 and dexamethasone was administered weekly at varying doses and administration routes.

The study was open to patients of all ages and did not have an upper cutoff for age, since transplantation was not involved, Landgren points out. Overall, the median age of patients in the study was 60 years old. A high-sensitivity, 8-color flow cytometry panel was utilized to assess minimal residual disease (MRD).

After administering the treatment to 45 patients, the overall complete response rate was 76%, states Landgren. All patients tested MRD-negative following the initial 8 cycles of therapy.

The key questions for this research going forward, Landgren states, is whether the MRD-negative rate persists in patients on maintenance therapy. Additionally, the MRD rate following a complete course of maintenance therapy will be the topic of future discovery.

Related Articles
New MRD Assay Helps Move Testing Forward in Multiple Myeloma Research
An improved assay for assessing MRD status in patients with multiple myeloma is contributing to the momentum for using MRD as a surrogate endpoint for survival in clinical trials and as a tool with the potential to help guide therapy choices.
Role of Lapatinib in HER2-Positive Breast Cancer
In this segment, panelists discuss the role of the TKI lapatinib in the adjuvant, neoadjuvant, and metastatic setting for patients with HER2-positive breast cancer.
Current Status of Immunotherapy in NSCLC
Panelists discuss ongoing clinical trials and research investigating immune checkpoint inhibitors as treatment for patients with non-small cell lung cancer.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.